Anna B. Halpern

Dr. Anna B. Halpern is an Academic Associate Professor in the Division of Hematology and Oncology at the University of Washington and an Associate Professor in the Clinical Research Division at Fred Hutch Cancer Center in Seattle, Washington. She specializes in hematologic malignancies with a particular focus on myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia.

Education:

• M.D. from Brown University
• Residency in Internal Medicine at University of Chicago
• Fellowship in Hematology-Oncology at UW/Fred Hutch

Dr. Halpern's research focuses on improving outcomes for adults with hematologic malignancies through evidence-based, rational therapies tailored to individual patients. She designs and conducts clinical trials for patients with myeloid neoplasms and uses large databases to study systems-issues such as risk factors for treatment toxicities. As Principal Investigator, she leads multiple clinical trials for advanced myeloid neoplasms and has published extensively on treatment optimization in acute myeloid leukemia.

Analysis of Dr. Halpern's recent publications reveals a consistent focus on acute myeloid leukemia treatment optimization, risk stratification, and comparative effectiveness research. Her work spans clinical trials, observational studies using large databases, and reviews of best practices in hematologic malignancy care, with particular attention to treatment settings (community vs. academic), performance status impact, and novel therapeutic approaches.

Professional Activities:

• Principal Investigator for multiple clinical trials for advanced myeloid neoplasms
• Active contributor to hematology/oncology literature with over 50 publications
• Board certified in Internal Medicine, Hematology, and Medical Oncology

Dr. Halpern maintains an active clinical practice at Fred Hutch Cancer Center - South Lake Union, where she sees patients with hematologic malignancies. She works to design personalized cancer care plans that balance patient and family needs with disease characteristics and the latest scientific advances and clinical trials.